

Press Release

Granules India's Net Profit grew by 72% to INR 60 Cr.

Hyderabad, January 29, 2019: Granules India Ltd., a growing pharmaceutical manufacturing company, announced today its financial results for the third quarter ended 31st December 2018.

CONSOLIDATED FINANCIALS	Q3 FY'19	Y-o-Y Growth
TOTAL INCOME	INR 638 Crs.	55%
EBITDA	INR 119 Crs.	59%
PAT	INR 60 Crs.	72%

The Company's Board of Directors has approved third interim dividend of 25 paise per share of face value of Re. 1 each.

The Board has appointed Mr. Robert George Cunard as an Additional Director, categorized as Independent. A brief profile of Mr. Cunard is enclosed in the press release.

"We are pleased with the strong growth in Revenue and Profit for this quarter as compared to the corresponding quarter of the previous year, driven by better sales from FD segment and increased contribution from North American market. Progress on our nine months period for this year is also very encouraging. During this nine months period, our Revenue from Operations and Net Profit have grown significantly as compared with the corresponding period of the last financial. The results of our concentrated efforts are visible in our sustained margins of over 18% for the reporting quarter and year till date financials. Fiscal prudence has enabled us to improve our debt ratios and working capital cycle. In this quarter, contribution from our JVs were sluggish due to cyclical nature of our CRAMs business and the routine annual maintenance shut down at our JV facility in China, but we expect the JVs to contribute meaningfully in subsequent quarters.

We have surpassed the targets we set for ourselves for the current financial year in the first nine months itself and the performance of fourth quarter will augment current growth. We will continue to deliver sustainable results in coming years by launching new products and optimally utilizing our capacities." said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited.



Brief profile of Mr. Robert George Cunard

Mr. Robert George Cunard holds Bachelor Degree in Arts from the University of Pittsburgh in Business Economics. Mr. Cunard brings more than 25 years of experience in US pharmaceuticals from the perspectives of wholesaler, retailer, and manufacturer.

Mr. Cunard is currently an Operating Partner, with HealthEdge Investment Partners, a US healthcare focused private equity fund. Prior to HealthEdge, Mr. Cunard was CEO of Aurobindo Pharma USA, Inc., the subsidiary of Aurobindo Pharma Limited. In the past, Mr. Cunard also held important positions in Mylan Laboratories and Teva Pharmaceuticals.



About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules support customers with unique value, extensive product range, and proactive solutions. The Company's global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K. The Company has 8 manufacturing facilities out of which 6 are located in India, 1 in China and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Contacts:

Sumanta Bajpayee
Corporate Finance & Investor Relations
040-30663572
sumanta.bajpayee@granulesindia.com

Chaitanya Tummala
Company Secretary
040-30663614
chaitanya.tummala@granulesindia.com

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.